All Companies

3D Bio Corporation
De­vel­op­ing scal­able bio­print­ed car­ti­lage ther­a­peu­tics to ad­dress un­met med­i­cal needs in re­con­struc­tive and or­tho­pe­dic in­di­ca­tions with rapid reg­u­la­to­ry path­way to mar­ket. Fil­ing IND for or­phan... [more in­for­ma­tion]
4D Molecular Therapeutics
Fo­cused on the dis­cov­ery and de­vel­op­ment of pro­pri­e­tary tar­get­ed AAV gene ther­a­py vec­tors and ther­a­peu­tic prod­ucts through a ro­bust dis­cov­ery plat­form, termed Ther­a­peu­tic Vec­tor Evo­lu­tion. Th­ese... [more in­for­ma­tion]
Abide Tx
Com­pany de­vel­op­ing serine-hy­dro­lase-tar­get­ed ther­a­peu­tics to work through en­do­cann­abi­noid path­ways to ad­dress neu­ro­log­i­cal di­s­or­ders with limit­ed treat­ment op­tions. Re­port­ed pos­i­tive phase 1b re­sults... [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] US$154 MM MCap
Re­sub­mit DSU­VIA NDA in Q2 fol­low­ing Type A meet­ing with FDA in Jan­uary. De­vel­op­ing non-in­va­sive tech­nol­o­gy, which de­liv­ers sufen­tanil sublin­gual tablets for pa­tients ex­pe­ri­enc­ing mod­er­ate-to-se­vere... [more in­for­ma­tion]
Adamas Pharmaceuticals, Inc. [ADMS] US$735 MM MCap
Fo­cused on de­vel­op­ing drugs for chron­ic neu­ro­log­i­cal di­s­or­ders by uti­l­iz­ing time-de­pen­dent bi­ol­o­gy to match ther­a­peu­tic drug pro­files with dis­ease pat­terns to drive a more sig­ni­f­i­cant durable ef­fect. [more in­for­ma­tion]
Advantagene Inc.
De­vel­op­ing a dif­fer­en­ti­at­ed I-O plat­form, us­ing pro­pri­e­ty gene me­di­at­ed cy­to­tox­ic im­munother­a­py (GM­CI) plat­form to de­vel­op treat­ments for solid tu­mors. ProsA­tak in Ph3 go­ing af­ter new­ly di­ag­nosed... [more in­for­ma­tion]
Affimed N.V. [AFMD] US$111 MM MCap
En­gi­neer­ing NK cell and T-cell en­gag­ing bis­pe­cif­ic anti­bodies and Tris­pe­cif­ic Abs. Lead pro­gram AFM13(CD30/CD16A) in a Ph 1b com­bo with Keytru­da for Hodgkins Lym­pho­ma. AFM13 - Ph 2a monother­a­py for... [more in­for­ma­tion]
Amarin Corporation [AMRN] US$870 MM MCap
Fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of ther­a­peu­tics to im­prove car­dio­vas­cu­lar health. Vas­ce­pa is the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in... [more in­for­ma­tion]
Apricus Biosciences, Inc. [APRI] US$9 MM MCap
Ad­vanc­ing medicines in urol­o­gy and rheu­ma­tol­o­gy, with two prod­uct can­di­dates in de­vel­op­ment. Fo­cused on U.S. ap­pro­val of Vi­taros, a top­i­cal gel for erec­tile dys­func­tion; NDA re-sub­mitt­ed in Q3 2017... [more in­for­ma­tion]
Aquinox Pharmaceuticals, Inc. [AQXP] US$70 MM MCap
Dis­cov­er­ing and de­vel­op­ing tar­get­ed ther­a­peu­tics in in­flam­ma­tion and im­muno-on­col­o­gy. Lead as­set, Rosip­tor, is an oral, once dai­ly, small molecule ac­ti­va­tor of SHIP1. In Ph3 for the treat­ment of... [more in­for­ma­tion]
A pri­vate, clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany that has lev­er­aged its plat­form of benz­imi­da­zole deri­va­tives to de­vel­op a ro­bust drug pipe­line of oral­ly avai­l­able, po­tent, and se­lec­tive small... [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung... [more in­for­ma­tion]
AxoGen [AXGN] US$2,094 MM MCap
Rev­enue gen­er­at­ing, ded­i­cat­ed to pe­ripher­al nerve re­pair with a port­fo­lio of re­gen­er­a­tive medicine prod­ucts avai­l­able in the US, Ca­na­da and sev­er­al other coun­tries. Prod­ucts in­clude Avance Nerve... [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. [BLCM] US$340 MM MCap
De­vel­op­ing CAR T/TCR ther­a­pies with molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­abling phar­ma­co­log­ic con­trol over cells for en­hanced safe­ty and ef­fi­ca­cy. Mul­ti­ple Ph 1/2 trials are un­der­way:... [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr1,838 MM MCap
Ber­Gen­Bio ASA is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on de­vel­op­ing a pipe­line of first-in-class AXL ki­nase in­hibi­tors as a po­ten­tial corn­er­s­tone of com­bi­na­tion can­cer ther­a­py. The... [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$1,467 MM MCap
De­vel­op­ing a port­fo­lio of in­no­va­tive, late-stage prod­uct can­di­dates tar­get­ing neu­ro­log­i­cal dis­eas­es, in­clud­ing rare di­s­or­ders. Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP... [more in­for­ma­tion]
BioPharmX [BPMX] US$38 MM MCap
Der­ma­tol­o­gy-fo­cused, de­vel­op­ing BPX-01 for top­i­cal mino­cy­c­line acne and rosacea treat­ment, based on its nov­el hy­drophil­ic top­i­cal for­mu­la­tion tech­nol­o­gy. Re­port­ed Ph 2b da­ta with BPX-01 in acne. Phase... [more in­for­ma­tion]
Bonesupport AB [STO-BONEX]
Or­tho­bi­o­log­ics com­pany that de­vel­ops and mar­kets CE­R­A­MENT®, an in­no­va­tive range of ra­dio­paque in­jectable os­teo­con­duc­tive and drug-elut­ing bio­ce­ram­ic prod­ucts that have a proven abil­i­ty to heal... [more in­for­ma­tion]
Camurus AB [CAMX:ST] SKr3,681 MM MCap
Com­bines pro­pri­e­tary Fluid­Crys­tal® for­mu­la­tion for sol­u­bi­l­iza­tion and sta­bi­l­iza­tion with ac­tive phar­ma­ceu­ti­cal sub­s­tances. Lead prod­uct is CAM2038, for Opi­oid de­pen­dence. Phase III read­out showed... [more in­for­ma­tion]
CASI Pharmaceuticals
A bio­phar­ma­ceu­ti­cal com­pany fo­cused on the ac­qui­si­tion, de­vel­op­ment, and com­mer­cial­iza­tion of in­no­va­tive ther­a­peu­tics ad­dress­ing CAN­CER and other un­met med­i­cal needs for the glob­al mar­ket, with a... [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$325 MM MCap
De­vel­op­ing Fir­dapse for the treat­ment of or­phan dis­ease in­di­ca­tion, Lam­bert-Ea­ton Myas­thenic Syn­drome (LEMS) with pos­i­tive Ph 3 da­ta and ad­di­tio­n­al Ph 3 trial re­sults ex­pect­ed in 2017. Mul­ti­ple... [more in­for­ma­tion]
Cellectis SA [CLLS] US$1,272 MM MCap
Lead­er in en­gi­neered al­lo­gene­ic (off-the-shelf) CAR-T ther­a­peu­tics. Pipe­line in­cludes pro­pri­e­tary pro­grams and Pfiz­er and Servi­er part­n­er­ships on nu­mer­ous tar­gets in on­col­o­gy. Lead in­ter­nal pro­gram... [more in­for­ma­tion]
CTI BioPharma [CTIC] US$231 MM MCap
New mgmt team and clin­i­cal di­rec­tion, re­cent­ly raised $69M. Lead can­di­date is pa­cri­tinib (JAK2 in­hibi­tor) for treat­ment of pts w myelo­fi­bro­sis. Ex­pects in­ter­im anal­y­sis for PAC203 Ph 2 dose-rang­ing... [more in­for­ma­tion]
CureVac AG
One of the big 3 mR­NA com­pa­nies (Ger­many-based). MOA: Se­quence-op­ti­mized, un­mod­i­fied mR­NA. In­tra­tu­mo­ral ther­a­py Ph1 trial (mul­ti­ple on­col­o­gy in­di­ca­tions) ini­ti­at­ed Q4 2017. Pro­phy­lac­tic vaccine... [more in­for­ma­tion]
Enzo Biochem, Inc. [ENZ] US$232 MM MCap
De­vel­op re­search tools, di­ag­nos­tics and ther­a­peu­tics and pro­vides ref­er­ence lab­o­ra­to­ry ser­vices to the med­i­cal com­mu­ni­ty. Ac­tiv­i­ties in­clude R&D, man­u­fac­tur­ing and mar­ket­ing of biomed­i­cal re­search... [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$45 MM MCap
Evofem is a wo­m­en’s health com­pany de­vel­op­ing an on-de­mand, non-hor­mo­n­al gel con­tra­cep­tive. Lead can­di­date, Am­pho­ra, is cur­rent­ly in Phase 3 de­vel­op­ment for con­tra­cep­tion. The Com­pany ex­pects to... [more in­for­ma­tion]
Formation Biologics
For­ma­tion Bio is a bio­phar­ma­ceu­ti­cal drug de­vel­op­ment com­pany. The com­pany was formed in 2011 as a spin out from YM Bio­S­ciences Inc., pri­or to YM's ac­qui­si­tion by Gilead. The com­pany was estab­lished... [more in­for­ma­tion]
Forward Pharma A/S [FWP] US$128 MM MCap
IP-gat­ed ac­cess to fu­ture roy­al­ties on lead­ing MS drug Tec­fidera® in US and EU de­pen­dent on up­com­ing le­gal de­ci­sions ex­pect­ed in 2018. [more in­for­ma­tion]
Genfit SA [GNFTF] US$910 MM MCap
Lead pro­gram Ela­fi­branor is a PPAR al­pha/del­ta ag­on­ist in Ph 3 for NASH and Ph 2 for PBC. At EASL in April, 2018, ex­pect to pro­vide an up­date on the en­roll­ment of the first group of ap­prox­i­mate­ly... [more in­for­ma­tion]
GenSight Biologics [SIGHT:PA] €56 MM MCap
Gene ther­a­pies for se­vere reti­nal and CNS de­gen­er­a­tive patholo­gies. Lead prod­uct, GS010, is in Ph3 for the treat­ment of Le­ber Hered­i­tary Op­tic Neu­ro­pa­thy (LHON) with da­ta ex­pect­ed in 2018. Pipe­line... [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$4,235 MM MCap
Chi­na-based glob­al­ly-fo­cused health­care group which re­search­es, de­vel­ops, man­u­fac­tures and sells phar­ma­ceu­ti­cals and health-re­lat­ed con­sumer prod­ucts. Its In­no­va­tion Plat­form fo­cus­es on dis­cov­er­ing... [more in­for­ma­tion]
Idera Pharmaceuticals, Inc. [IDRA] US$212 MM MCap
Lead can­di­date IMO-2125 is used in com­bi­na­tion with Ip­ilu­mumab in PD1 re­frac­to­ry me­lano­ma pa­tients. Ph 3 trial ini­ti­a­tion is planned for 1Q18; Idera cont­in­ues to en­roll more pa­tients in­to their Ph 2... [more in­for­ma­tion]
Inspirion Delivery Sciences LLC
(Pri­vate­ly held) Mor­phaBond ER™ US com­mer­cial launch Nov 2017 (FDA-ap­proved, first sin­gle-en­ti­ty abuse de­ter­rent ER mor­phine prod­uct) and Rox­y­Bond™ (FDA ap­proved, first and on­ly IR abuse-de­ter­rent... [more in­for­ma­tion]
Loxo Oncology, Inc. [LOXO] US$5,346 MM MCap
De­vel­ops tar­get­ed drugs for the treat­ment of can­cer in ge­net­i­cal­ly defined pa­tient pop­u­la­tions. Lead pro­gram: pur­pose built pan TRK in­hibi­tor in a Ph 2 solid tu­mor study with FDA break­through... [more in­for­ma­tion]
Marinus Pharmaceuticals [MRNS ] US$320 MM MCap
Mar­i­nus Phar­ma­ceu­ti­cals, Inc. is a bio­phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to the de­vel­op­ment of ga­nax­olone, which of­fers a new mech­anism of ac­tion, de­mon­s­trat­ed ef­fi­ca­cy and safe­ty, and con­ve­nient dos­ing... [more in­for­ma­tion]
Medigene AG [MDG1:DB] €311 MM MCap
TCR tar­get­ing PRAME (AML, MDS, MM) en­tered clin­ic March 2018. CTA sub­mitt­ed for TCR tar­get­ing MAGE-A1 (MM, liv­er, and lung can­cer); sev­er­al add'l undis­closed tar­gets & in­di­ca­tions in PC dev't. DC vax... [more in­for­ma­tion]
Medivir AB [MVIR.B:ST] SKr983 MM MCap
Broad pipe­line of clin­i­cal stage as­sets in­clud­ing remeti­no­s­tat, a Ph 3 ready top­i­cal HDAC in­hibi­tor for the treat­ment of ear­ly-stage cu­ta­neous T-cell lym­pho­ma (CT­CL). Re­cent­ly an­nounced to­p­line da­ta... [more in­for­ma­tion]
Meves Pharmaceuticals, Inc.
Meves Phar­ma­ceu­ti­cals, Inc. is de­vel­op­ing nu­cle­o­side based ther­a­pies for mi­to­chon­drial DNA (mtD­NA) de­ple­tion syn­dromes (MDS or MDDS), a cat­e­go­ry of se­vere ge­net­ic dis­eas­es. The ini­tial fo­cus is on... [more in­for­ma­tion]
Minerva Neurosciences, Inc. [NERV] US$316 MM MCap
Ph 3 trial w/rolu­peri­done tar­get­ing neg­a­tive symp­toms as­soc w/ schi­zophre­nia; du­al MOA (5-HT2A & Sig­ma2 an­ta­g­on­ist); top-line da­ta 1H19. 3 Ph 2b trials on­go­ing w/ sel­torex­ant, in­clud­ing two in MDD and... [more in­for­ma­tion]
Motif Bio plc [MTFB] US$133 MM MCap
Antibi­ot­ic com­pany (pos­i­tive Ph 3 da­ta an­nounced; rolling NDA sub­mis­sion com­plet­ed) fo­cused on gram-pos­i­tive in­fec­tions caused by mul­ti-drug re­sis­tant bac­te­ria. To­p­line re­sults with Iclaprim in... [more in­for­ma­tion]
CNS com­pany de­vel­op­ing the first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 is in Phase 2b/3 de­vel­op­ment (SPA and Fast Track Desig­na­tion by FDA)... [more in­for­ma­tion]
NexImmune, Inc.
Pri­vate IO com­pany de­vel­op­ing a unique ap­proach to anti­gen-spe­cif­ic T cell ther­a­py. Tech­nol­o­gy us­es syn­thet­ic nano­par­ti­cles de­c­o­rat­ed with a com­bi­na­tion of mul­ti­ple tu­mor rel­e­vant anti­gens and... [more in­for­ma­tion]
Omeicos Therapeutics
OME­I­COS Ther­a­peu­tics has dis­cov­ered a se­ries of metaboli­cal­ly ro­bust syn­thet­ic ana­logues of ome­ga-3 fat­ty acid-de­rived epoxye­i­cosanoids that have the po­ten­tial to treat in­flam­ma­to­ry, car­dio­vas­cu­lar... [more in­for­ma­tion]
OncoMed Pharmaceuticals [OMED] US$90 MM MCap
Cel­gene part­n­er­ship with near-term po­ten­tial mile­s­tones of $98M for an­ti-TIG­IT, ros­man­tuzumab (RSPO3 fu­sions) and navi­cix­izumab (an­ti-DL­L4/VEGF bis­pe­cif­ic) a clin­i­cal-stage com­pany dis­cov­er­ing and... [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr7,584 MM MCap
De­vel­op­ing Yga­lo (melflufen), a next gen­er­a­tion alky­la­tor that pref­er­en­tial­ly tar­gets can­cer cells via pep­ti­dase tar­get­ing, for mul­ti­ple myelo­ma. Yga­lo over­comes re­sis­tance mech­anisms that im­pact... [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
De­vel­op­ing treat­ments for the un­der­ly­ing caus­es of can­cer and CNS dis­eas­es by tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A), an epi­ge­net­ic hi­s­tone mod­i­fy­ing en­zyme. Lead CNS com­pound... [more in­for­ma­tion]
Fo­cused on anes­th­e­sia around game chang­ing as­set Remi­ma­zo­lam, a short-act­ing anes­thet­ic. Remi­ma­zo­lam com­plet­ed a pos­i­tive Ph 3 in pro­ce­du­ral se­da­tion in the US. Pos­i­tive safe­ty da­ta in ASA III/IV... [more in­for­ma­tion]
PharmaMar SA [PHM:MA]
1H 2017 to­tal rev­enues of &eu­ro;96.9M. Yon­delis for soft tis­sue sar­co­ma and ovarian can­cer is com­mer­cial­ized with a di­rect sales-force in Eu­rope and part­n­er­ship in US with Janssen. Zep­syre cur­rent­ly in... [more in­for­ma­tion]
Pharming Group NV [PHARM.AS]
Lead RU­CON­EST is an rhC1-es­terase in­hibi­tor mar­ket­ed to treat an­gioede­ma at­tacks in pa­tients with HAE with 100% re­sponse rate, no re­lapse, side ef­fects, or plas­ma risk. Com­plet­ed Ph II for pro­phy­laxis... [more in­for­ma­tion]
PhaseBio Pharmaceuticals, Inc.
Clin­i­cal-stage, de­vel­op­ing new and im­proved bio­ther­a­peu­tics for the treat­ment of or­phan dis­eas­es, with an ini­tial fo­cus on car­diopul­mo­nary di­s­or­ders. Pro­pri­e­tary tech­nol­o­gy plat­form us­es re­com­bi­nant... [more in­for­ma­tion]
Phosphagenics [PPGNY] US$19 MM MCap
Phos­pha­gen­ics is a re­search-based biotech­nol­o­gy com­pany that dis­cov­ers and de­vel­ops new ways to en­hance the de­liv­ery, ef­fec­tive­ness, and/or tol­er­a­bil­i­ty of proven phar­ma­ceu­ti­cal, con­sumer and an­i­mal... [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$300 MM MCap
De­vel­op­ing an­ti­calins (re­com­bi­nant pro­teins dif­fer­en­ti­at­ed from MAbs) for can­cer, se­vere asth­ma and ane­mia. PRS-060 As­traZene­ca part­n­er pro­gram first sub­ject en­rolled in De­cem­ber 2017. Co-de­vel­op­ment... [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Third Rock Ven­tures found­ed and fund­ed com­pany har­ness­ing the ther­a­peu­tic po­ten­tial of in­te­grin bi­ol­o­gy and TGF-be­ta mo­d­u­la­tion. - Build­ing a pa­tient reg­istry for cer­tain ar­eas of fi­brot­ic dis­ease to... [more in­for­ma­tion]
Poxel SA
De­vel­op­ing safer and more ef­fec­tive ther­a­pies for metabolic dis­eas­es. Imeglimin (a mi­to­chon­dria-based MOA) for Type 2 di­a­betes be­gan Ph 3 trial in Ja­pan with Asian part­n­er Su­m­i­t­o­mo Dainip­pon. [more in­for­ma­tion]
Probiodrug AG [PRBGF] US$141 MM MCap
Pos­i­tive da­ta from Ph 2a (SAPHIR) clin­i­cal trial for PQ912, for Alzheimer’s Dis­ease (AD), with study de­sign for Ph 2b core pro­gram de­tailed in April 2018. MOA: first in class small molecule QC... [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$167 MM MCap
Pro­ta­g­on­ist uti­l­izes a pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op first-in-class oral tar­get­ed ther­a­py-based drugs that work by block­ing bi­o­log­i­cal path­ways that are cur­rent­ly tar­get­ed by... [more in­for­ma­tion]
Protalix BioTherapeutics [PLX] US$65 MM MCap
Fo­cused on re­com­bi­nant ther­a­peu­tic pro­teins pro­duced us­ing Pro­CellEx®, a plant cell-based pro­tein ex­pres­sion sys­tem. ELELY­SO is FDA-ap­proved for Gauch­er dis­ease. Lead pipe­line as­set, PRX-102, a... [more in­for­ma­tion]
Pulse Biosciences, Inc. [PLSE] US$232 MM MCap
A de­vel­op­ment-stage med­i­cal de­vice com­pany us­ing a nov­el and pro­pri­e­tary plat­form tech­nol­o­gy called Nano-Pulse Elec­tro-Sig­nal­ing or NPES. NPES is a lo­cal and drug-free tech­nol­o­gy that uti­l­izes... [more in­for­ma­tion]
ReNeuron Group plc [RENE:LN] GBX31 MM MCap
Clin­i­cal-stage, UK-based cell ther­a­py com­pany with al­lo­gene­ic, off-the-shelf can­di­dates: chron­ic stroke dis­a­bil­i­ty (Ph3 trial de­sign ap­proved by FDA, ini­ti­a­tion mid 2018); re­tini­tis pig­men­tosa (Ph1/2... [more in­for­ma­tion]
Rigel Pharmaceuticals [RIGL] US$463 MM MCap
Rigel Phar­ma­ceu­ti­cals is ded­i­cat­ed to dis­cov­er­ing, de­vel­op­ing and pro­vid­ing nov­el small molecule drugs for im­mune and he­ma­to­log­ic di­s­or­ders, can­cer and rare dis­eas­es. The com­pany's first FDA ap­proved... [more in­for­ma­tion]
Savara Inc. [SVRA] US$382 MM MCap
De­vel­ops in­ha­la­tion ther­a­pies for the treat­ment of pa­tients with rare pul­mo­nary con­di­tions. Three pipe­line prod­ucts: Mol­gradex, an in­haled ne­b­u­l­ized GM-CSF to treat Pul­mo­nary Alve­o­lar Pro­tei­no­sis... [more in­for­ma­tion]
Shenzhen Yuanxin
[more in­for­ma­tion]
Stemline Therapeutics, Inc. [STML] US$487 MM MCap
Three clin­i­cal stage prod­uct can­di­dates. SL-401, an IL-3/CD123 tar­get­ed ther­a­py for BPD­CN, com­plet­ed re­cruit­ment of its piv­o­tal Ph 2 has Break­through Desig­na­tion for the treat­ment of pa­tients with... [more in­for­ma­tion]
STRATEC Biomedical AG [SBS:FF] €816 MM MCap
Mar­ket lead­er in au­to­ma­tion sys­tems and soft­ware for the di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS... [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$241 MM MCap
A com­mer­cial-stage com­pany fo­cused on ther­a­pies for rare dis­eas­es. KEVEYIS is the first and on­ly treat­ment ap­proved pe­ri­od­ic par­tial paral­y­sis; 2018 rev­enue gui­dance of $18-20M. MACRILEN is ap­proved... [more in­for­ma­tion]
Sutro Biopharma
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and mul­ti-spe­cif­ic anti­body-based ther­a­peu­tics for can­cer ther­a­py. The com­pany’s dis­cov­ery and de­vel­op­ment ef­forts are driv­en by... [more in­for­ma­tion]
Syneos Health [SYNH] US$5,021 MM MCap
[more in­for­ma­tion]
Taiwan Liposome Company (TLC) [4152-TW]
Li­po­some de­liv­ery plat­form com­pany fo­cused on pain ma­n­age­ment, oph­thal­mol­o­gy, and on­col­o­gy. Lead pro­grams in Ph 2 trials in­clude TL­C599 in knee OA pain, TL­C399 in oph­thal­mol­o­gy / mac­u­lar ede­ma, and... [more in­for­ma­tion]
Targovax [TRVX:OS] NKr660 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pa­tients w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2018 and 2019. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]
TCR2 Therapeutics
Pro­pri­e­tary TRuC™ plat­form based on T cell re­cep­tor fu­sion con­structs that em­ploy the full sig­nal­ing pow­er of the T cell re­cep­tor (TCR). This cell ther­a­py ap­proach al­lows per­sis­tent killing of solid... [more in­for­ma­tion]
Tessa Therapeutics
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the treat­ment of can­cer by redi­rect­ing the body’s po­tent an­ti-vi­ral im­mune re­sponse to rec­og­nize and kill can­cer cells. Tes­sa’s core... [more in­for­ma­tion]
Valbiotis [ALVAL]
VAL­BI­O­TIS spe­cial­izes in de­vel­op­ing in­no­va­tive nu­tri­tion so­lu­tions de­signed to pre­vent car­diometabolic dis­eas­es and pro­vide nu­tri­tio­n­al sup­port for pa­tients. [more in­for­ma­tion]
Vericel Corporation [VCEL] US$378 MM MCap
Au­tol­o­gous cell ther­a­py com­pany, mar­ket­ing au­tol­o­gous cell ther­a­py prod­ucts in the US. MA­CI is the com­pa­nies prod­uct for car­ti­lage re­pair, which is a >$700m/yr mar­ket. Al­so mar­kets Epi­cel for skin... [more in­for­ma­tion]
Verseon [VSN-LON]
Verseon was found­ed in 2002. Its pro­pri­e­tary drug dis­cov­ery plat­form, de­vel­oped en­tire­ly in-house, is the prod­uct of over ten years of re­search and de­vel­op­ment. The com­pany’s plat­form is the first... [more in­for­ma­tion]
Veru Healthcare [VERU] US$115 MM MCap
De­vel­op­ing and com­mer­cial­iz­ing phar­ma­ceu­ti­cals and de­vices in urol­o­gy and on­col­o­gy. Uti­l­izes the 505(b)(2) path­way for more eco­nom­i­cal and fast-track ap­pro­val pro­cess­es. Prod­uct can­di­dates are for... [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] US$51 MM MCap
Late-stage, Ph. 3 Alzheimer's da­ta read-out ear­ly 2018. Azeli­ra­gon - oral, small-molecule in­hibi­tor of the Re­cep­tor for Ad­vanced Gly­ca­tion End­prod­ucts (RAGE), lies up­stream to AD patholo­gies like... [more in­for­ma­tion]
Wilson Therapeutics [WTX:ST] SKr6,493 MM MCap
Fo­cused on rare dis­eas­es. Ex­pects to ad­vance WTX101, a nov­el first-in-class cop­per-pro­tein-bind­ing agent for treat­ment of Wil­son Dis­ease in­to piv­o­tal Phase 3 FO­CuS study in ear­ly 2018; grant­ed OD in... [more in­for­ma­tion]
Yisheng Biopharma
[more in­for­ma­tion]
ZIOPHARM Oncology Inc [ZIOP] US$439 MM MCap
A Bos­ton, Mas­sachusetts-based biotech­nol­o­gy com­pany em­ploy­ing nov­el gene ex­pres­sion, con­trol and cell tech­nolo­gies to de­liv­er safe, ef­fec­tive and scal­able cell-based ther­a­pies for the treat­ment of... [more in­for­ma­tion]